Sarepta Therapeutics, Inc. (SRPT) NASDAQ

Currency In USD

Key Executives

Name	Title	Pay	Year Born
Douglas S. Ingram	Chief Executive Officer & Director	1.84M	1963
Joseph Bratica	Controller & Vice President	438,513	1964
Ryan H. Wong	Executive Vice President & Chief Financial Officer	633,899	1979
Cristin L. Rothfuss	Executive Vice President, General Counsel & Company Secretary	806,778	1968
Ian Michael Estepan	President & Chief Operating Officer	1.02M	1976
Louise R. Rodino-Klapac	President of Research & Development and Technical Operations	1.03M	1978
Rachael Potter	Chief Scientific Officer	0	N/A
Diane L. Berry	Executive Vice President and Chief of Global Policy & Advocacy Officer	0	N/A
Tamara Thornton	Director of Finance, Treasury & Investor Relations	0	N/A
Mary Jenkins	Senior Manager of Investor Relations	0	N/A
Alison Nasisi	Executive Vice President & Chief People Officer	0	N/A
Patrick Moss	Executive Vice President & Chief Commercial Officer	0	N/A
James Richardson	Executive VP & Chief Medical Officer	0	N/A

Name

Title

Pay

Year Born

Douglas S. Ingram

Chief Executive Officer & Director

1.84M

1963

Joseph Bratica

Controller & Vice President

438,513

1964

Ryan H. Wong

Executive Vice President & Chief Financial Officer

633,899

1979

Cristin L. Rothfuss

Executive Vice President, General Counsel & Company Secretary

806,778

1968

Ian Michael Estepan

President & Chief Operating Officer

1.02M

1976

Louise R. Rodino-Klapac

President of Research & Development and Technical Operations

1.03M

1978

Rachael Potter

Chief Scientific Officer

N/A

Diane L. Berry

Executive Vice President and Chief of Global Policy & Advocacy Officer

N/A

Tamara Thornton

Director of Finance, Treasury & Investor Relations

N/A

Mary Jenkins

Senior Manager of Investor Relations

N/A

Alison Nasisi

Executive Vice President & Chief People Officer

N/A

Patrick Moss

Executive Vice President & Chief Commercial Officer

N/A

James Richardson

Executive VP & Chief Medical Officer

N/A

Description

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company dedicated to the discovery and advancement of genetic treatment modalities, including RNA-targeted therapeutics and gene therapies, specifically for rare diseases. The company currently offers two approved treatments: EXONDYS 51, prescribed for Duchenne muscular dystrophy (DMD) patients with confirmed dystrophin gene mutations amenable to exon 51 skipping, and VYONDYS 53, for DMD patients with exon 53 skipping mutations. Sarepta's development pipeline includes AMONDYS 45, an exon-skipping product candidate utilizing phosphorodiamidate morpholino oligomer chemistry for exon 45; SRP-5051, a peptide-conjugated PMO designed to target exon 51 of dystrophin pre-mRNA; and gene therapy programs such as SRP-9001 for DMD and SRP-9003 for limb-girdle muscular dystrophies. The company maintains collaborative agreements with organizations like F. Hoffman-La Roche Ltd, Nationwide Children's Hospital, Lysogene, Duke University, Genethon, and StrideBio. Founded in 1980, Sarepta Therapeutics is headquartered in Cambridge, Massachusetts.